Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Hims & Hers Health Inc (NYSE: HIMS) closed at $51.76 up 8.33% from its previous closing price of $47.78. In other words, the price has increased by $8.33 from its previous closing price. On the day, 34.36 million shares were traded. HIMS stock price reached its highest trading level at $52.49 during the session, while it also had its lowest trading level at $48.6.
Ratios:
For a deeper understanding of Hims & Hers Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 100.44. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.85.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65. TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 26 ’25 when Okupe Oluyemi sold 11,581 shares for $43.69 per share. The transaction valued at 505,968 led to the insider holds 116,806 shares of the business.
Boughton Soleil sold 2,571 shares of HIMS for $114,487 on Aug 25 ’25. The Chief Legal Officer now owns 150,450 shares after completing the transaction at $44.53 per share. On Aug 25 ’25, another insider, Boughton Soleil, who serves as the Officer of the company, bought 2,571 shares for $44.53 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 11265149952 and an Enterprise Value of 11598546944. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 64.78, and their Forward P/E ratio for the next fiscal year is 65.21. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.81 while its Price-to-Book (P/B) ratio in mrq is 20.77. Its current Enterprise Value per Revenue stands at 5.76 whereas that against EBITDA is 72.421.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.21, which has changed by 2.1237175 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $14.53. The 50-Day Moving Average of the stock is 3.08%, while the 200-Day Moving Average is calculated to be 23.47%.
Shares Statistics:
For the past three months, HIMS has traded an average of 35.70M shares per day and 26858140 over the past ten days. A total of 217.38M shares are outstanding, with a floating share count of 202.66M. Insiders hold about 10.34% of the company’s shares, while institutions hold 77.79% stake in the company. Shares short for HIMS as of 1756425600 were 74635929 with a Short Ratio of 2.09, compared to 1753920000 on 64593744. Therefore, it implies a Short% of Shares Outstanding of 74635929 and a Short% of Float of 40.919998.
Earnings Estimates
The current assessment of Hims & Hers Health Inc (HIMS) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.26, with high estimates of $0.31 and low estimates of $0.17.
Analysts are recommending an EPS of between $1.24 and $0.78 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.77 and $0.99.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $579.33M this quarter.It ranges from a high estimate of $590.87M to a low estimate of $567.56M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $401.56MFor the next quarter, 11 analysts are estimating revenue of $631.31M. There is a high estimate of $685.04M for the next quarter, whereas the lowest estimate is $592.7M.
A total of 13 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.41B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.34B. In the same quarter a year ago, actual revenue was $1.48BBased on 12 analysts’ estimates, the company’s revenue will be $2.8B in the next fiscal year. The high estimate is $3B and the low estimate is $2.5B.
